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Abstract: Epithelial ovarian cancer (EOC) is one of the leading causes of cancer deaths in 
women worldwide. Ubiquitin-conjugating enzyme 9 (Ubc9), the sole conjugating enzyme 
for sumoylation, regulates protein function and plays an important role in   
sumoylation-mediated cellular pathways. Although sumoylation plays a key role in DNA 
repair and tumorgenesis, whether Ubc9 is involved in EOC progression remains unknown. 
In the present study, we constructed Ubc-9 expressed recombined plasmid   
pEGFP-N1-Ubc9. The mRNA levels of Ubc9 were confirmed in human ovarian   
cell lines before and after transfection with pEGFP-N1-Ubc9 or small interfering   
RNA (siRNA) targeted Ubc9 by real-time polymerase chain reaction (PCR). The   
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to 
observe the effect of Ubc9 on cell proliferation. The protein levels of Ubc9, and 
proliferation-related signals Akt and physphorylated Akt were determined by Western blot. 
Our results showed that proliferation of EOC cells increased significantly in Ubc9 
overexpressing cells, but decreased in Ubc9 knockdown cells. The physphorylation of Akt 
showed similar trends. In addition, the inhibitor of PI3K/Akt signaling pathway, 
LY294002, dramatically inhibited the growth of Ubc9 overexpressing cells. Therefore, 
Ubc9 gene plays an important role in cell proliferation in EOC through PI3K/Akt   
signaling pathway. 
  
OPEN ACCESSInt. J. Mol. Sci. 2013, 14  11062 
 
 
Keywords: epithelial ovarian cancer (EOC); ubiquitin-conjugating enzyme 9 (Ubc9); 
proliferation; Akt 
 
1. Introduction 
Ovarian cancer is one of the most common causes of death from all cancers among women and the 
leading cause of death from gynecological malignancies. Epithelial ovarian cancer (EOC) is a common 
malignant ovarian neoplasm with poor five-year survival rate (less than 30%) without effective early 
diagnostic methods. Therefore, there is a critical need for better targeted therapies for ovarian cancers. 
Ubiquitin-conjugating enzyme 9 (Ubc9) is an essential E2 enzyme required for small   
ubiquitin-related modifier (SUMO) conjugation or sumoylation [1] and it transfers the activated 
SUMO to different cellular protein substrates [2]. Unlike ubiquitination that normally targets proteins 
for degradation through proteasome pathways, sumoylation has been implicated in the regulation of 
protein stability, protein-protein interactions, transcriptional activity, and subcellular localization [3,4]. 
In addition, recent evidence indicates that Ubc9 is a multifunctional protein that can exert its functions 
independent of sumoylation [5–7]. 
Ubc9 is a single-copy gene that is frequently up-regulated in tumors. Available evidence suggests 
that Ubc9 is a tumor-promoting factor. Ubc9 is up-regulated in several malignancies, such as lung 
adenocarcinoma, colorectal cancer, prostatic cancer, breast adenocarcinoma, melanoma and ovarian 
carcinoma [8–12]. However, the function of Ubc9 in EOC remains poorly understood.  
In the present study, we constructed Ubc-9 expressed recombined plasmid pEGFP-N1-Ubc9 and 
stably transfected EOC cell line overexpressing Ubc9. We found that the overexpression of Ubc9 gene 
can promote EOC cell proliferation. 
2. Results and Discussion 
2.1. Ubc9 mRNA and Protein Expression in Ovarian Cancer Cells 
We first examined that whether Ubc9 is expressed in ovarian epithelial carcinoma tissues in vivo. 
Immunohistochemical staining showed that Ubc9 was expressed in ovarian epithelial carcinoma tissue, 
but barely expressed in normal ovary tissue (Figure 1A). Three cell lines were screened for Ubc9 
mRNA and protein expression using real-time polymerase chain reactions (PCR) and Western blot 
(Figure 1B,C). Our results showed that the expression level of Ubc9 was the highest in A2780 cells 
and the lowest in HO-8910 cells both at mRNA and protein levels. Therefore, out of these three cell 
lines, HO-8910 cell was chosen for preparing Ubc9 stably overexpressing cells, because they showed 
relatively lower expression of Ubc9. 
2.2. Construction of Ubc9 Recombinant Plasmid and Selection of Stable Transfected Cell Clones 
To determine the effect of Ubc9 in the proliferation of HO-8910 cells, we prepared the Ubc9 stably 
overexpressing cells. First, we constructed pEGFP-N1-Ubc9 recombinant plasmid successfully, the 
sequence was verified by DNA sequencing. Then, the pEGFP-N1-Ubc9 plasmids were transfected into Int. J. Mol. Sci. 2013, 14  11063 
 
 
HO-8910 cells to create 10 stably transfected cell lines. Each positive clone was identified by Western 
blot analysis for expression of EGFP-Ubc9 (Figure 2). Clone 3 was used in the following experiments. 
Figure 1. Ubc9 was expressed in ovarian epithelial carcinoma in  vivo and in vitro.  
(A) Immunohistochemical analysis of sections from ovarian epithelial carcinoma samples 
or normal ovary samples with specific anti-Ubc9 antibody. Magnification is 400;  
(B) Relative Ubc9 mRNA expression in epithelial ovarian carcinoma cell lines; (C) Ubc9 
protein expression in epithelial ovarian carcinoma cell lines. 
 
Figure 2. Construction of Ubc9 recombinant plasmid and selection of stable transfected 
cell clones. The identification of Ubc9 stably overexpressing HO-8910 cells was performed 
by Western Blot. 
 
2.3. Specific Silencing of the Ubc9 Gene 
Three different Ubc9 siRNA and the scrambles were transfected into HO8910-Ubc9 cells 
separately. The Ubc9 mRNA and protein levels were assessed by real-time PCR and western blot 
analysis 48 h after transfection. As shown in Figure 3A, the inhibitory rate of Ubc9 siRNA1 was 
93.64% (p = 0.001), the inhibitory rate of Ubc9 siRNA2 was 57.32% (p = 0.006). However, there were 
no significant differences between the Ubc9 siRNA3 group and the scramble group (p  = 0.648).   
By using western blot analysis as shown in Figure 3B, Ubc9 siRNA2 was found to have the   
highest inhibitory rate 85.28% (p  = 0.01). Thus, we used Ubc9 siRNA1 and siRNA2 for   
subsequent experiments. 
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Figure 3. Identification of Ubc9 siRNA. (A) Identification of Ubc9 siRNA by real-time 
PCR. Relative mRNA levels were normalized to that with scramble siRNA treatment;   
(B) Ubc9 protein level in HO8910-Ubc9 cells treated with Ubc9 siRNA. The right panel 
represents the summary results of Ubc9 protein level. Relative protein levels were 
normalized to that with scramble siRNA treatment. Data are mean ± SEM from 3 separate 
experiments. * p < 0.05, ** p < 0.01 versus scramble group. 
 
2.4. Ubc9 Overexpression Promotes Cell Proliferation, whereas siRNA Targeting Ubc9 Inhibited 
Epithelial Ovarian Cancer Cell Proliferation 
We then studied the possible role of Ubc9 in epithelial ovarian carcinoma progression. 
Overexpression of Ubc9 significantly increased HO-8910 cell proliferation. The proliferation rate of 
the HO8910-Ubc9 cells was much higher than the HO-8910 cells (p = 0.001, p < 0.001, Figure 4A) 
and HO8910-pEGFP-N1 vector cells at 48 and 72 h (p = 0.022, p < 0.001, Figure 4A). There was no 
significance difference between the HO-8910 and HO8910-pEGFP-N1 vector cells at time point 24, 
48, 72 h (p = 0.067, p = 0.333, p = 0.226). 
To further investigate the role of Ubc9 in cell proliferation, we suppressed Ubc9 expression by 
Ubc9 specific siRNAs. HO8910-Ubc9 cell presented relatively higher expression of Ubc9 and siRNA1 
and2 were chosen for RNA interference. We measured the cell growth by MTT assay. As shown in 
Figure 4B, the proliferation rate was significantly inhibited by siRNA1 transfection compared with 
scramble group at 48, 72 h (p < 0.001, p < 0.001), and the proliferation rate of siRNA2 group was also 
inhibited compared with scramble group at 72 h (p < 0.001). 
  Int. J. Mol. Sci. 2013, 14  11065 
 
 
Figure 4. Effect of Ubc9 on HO-8910 cell proliferation. (A) HO-8910 cells were stably 
transfected with Ubc9 expressing plasmid or vectors and cell viability was detected with 
MTT assay. Data are means ± SEM from 3 separate experiments. * p < 0.01, ** p < 0.001 
compared with HO-8910 cells; (B) HO-8910 cells were transfected with siRNAs targeting 
Ubc9 or scramble siRNA and cell viability was detected with MTT assay. Data are means 
± SEM from 3 separate experiments. ** p < 0.001 compared with scramble transfection. 
 
2.5. PI3K/Akt Signaling is Required for Ubc9 in Accelerating HO8910 Cell Proliferation  
In growth factor signaling, activation of Akt has been implicated as a key step. As shown in   
Figure 5, phosphorylation of Akt protein was apparently increased in Ubc9 overpressing cells   
(Figure 5A) and decreased in Ubc9-knockdown cells (Figure 5B). Therefore, we then detected the role 
of Akt in Ubc9-augmented EOC cell proliferation. As shown in Figure 5C, after HO8910-Ubc9 cells 
were treated by LY294002 (25 μM), the cell proliferation rates were much lower than untreated 
HO8910-Ubc9 cells (p = 0.038) and DMSO(dimethylsulfoxide)-treated group (p = 0.003) at time point 
72 h. There was no significant difference between HO8910-Ubc9 and DMSO group (p = 0.717). These 
results indicated that involvement of Ubc9 in the proliferation of epithelial ovarian carcinoma was at 
least partially through the PI3K/Akt pathway. 
Figure 5. PI3K/Akt signaling is required for Ubc9 in accelerating HO-8910 cell 
proliferation. (A) Western blot profiles of Akt and p-Akt proteins in HO8910 and   
HO8910-Ubc9 cells; (B) Western blot profiles of Akt and p-Akt proteins in Scramble- and 
Ubc9-siRNA-transfected HO8910-Ubc9 cells; (C) The proliferation of HO8910-Ubc9 cells 
were inhibited after being treated with LY294002. Data are means ± SEM from 3 separate 
experiments. * p < 0.01, compared with DMSO-treated HO8910-Ubc9 cells. 
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Figure 5. Cont. 
 
2.6. Discussion 
The present study demonstrated that Ubc9 can promote the proliferation of human epithelial ovarian 
carcinoma cell line HO-8910 cells at least partially through a PI3K/Akt signaling pathway. This 
conclusion is supported by the following observations: (1) Ubc9 is expressed in EOC tissue in vivo;  
(2) Proliferation of EOC cells increased significantly in Ubc9 overexpressing HO-8910 cells, but 
decreased in Ubc9 knockdown HO-8910 cells; (3) Phosphorylation of Akt increased significantly in 
Ubc9 overexpressing HO-8910 cells, but decreased in Ubc9 knockdown HO-8910 cells; (4) Inhibition 
of PI3K/Akt signaling pathway by LY294002 dramatically inhibited the growth of Ubc9 
overexpressing HO-8910 cells. To the best of our knowledge, this is the first report demonstrating the 
involvement of Ubc9 in the proliferation of epithelial ovarian carcinoma. 
Sumoylation is the covalent attachment of SUMO to a target protein. Similar to other   
ubiquitin-like pathways, three enzyme types are involved that act in succession: an activating enzyme 
(E1), a conjugating enzyme (E2), and a ligase (E3). Protein sumoylation has been implicated in the 
regulation of protein stability, subcellular localization, and the activity of transcription factors [13,14]. 
Because Ubc9 is the sole E2-conjugating enzyme required for sumoylation, it is believed to play a 
central role in these processes. Ubc9 is well known for its key role in protein sumoylation and   
sumoylation-mediated cellular pathways, ultimately impacting tumor initiation and progression [12,15]. 
Dysregulation of Ubc9 may lead to alterations in the sumoylation process or may only affect the 
sumoylation modification of some key proteins, ultimately impacting cell growth and cancer development.  
As a multi-functional protein, some evidence suggests that Ubc9 can also promote breast cell 
invasion and metastasis in a sumoylation independent manner [8]. However, there is scarce 
information available in the literature as to whether and how Ubc9 impacts on ovarian cancer cells, 
although previous studies have reported that Ubc9 was up-regulated in ovarian cancer tissues and  
cells [12,16]. In this study, we introduced Ubc9 gene into human ovarian cancer cell line HO-8910 
cells through gene transfection and established cell model overexpressing Ubc9 gene stably. We found 
that Ubc9 can promote cell proliferation in EOC, which may give the potential target for EOC therapy 
in the future.  
PI3K/Akt signaling pathway is a critical pathway involved in cell survival and has been shown to be 
constitutively active in ovarian cancer cell lines [17]. We found that the phosporylation of Akt was Int. J. Mol. Sci. 2013, 14  11067 
 
 
increased in Ubc9 overpressing HO-8910 cells, but knockdown of endogenous Ubc9 resulted in 
suppression Akt phosporylation. Furthermore, Ubc9 related proliferation of HO-8910 cells can be 
inhibited by the inhibitor of a PI3K/Akt signaling pathway, LY294002. Hence, we infer that PI3K/Akt 
signaling is required for Ubc9 in accelerating HO8910 cell proliferation. A number of studies have 
demonstrated that the patients with activated Akt had a significant survival disadvantage compared to 
patients with lower level of Akt phosphorylation, and the patients with ovarian cancer suggested Akt 
phosphorylation as an independent prognostic indicator [16,18,19]. To our knowledge, this is the first 
report showing that overexpression of Ubc9 could significantly enhance proliferation of ovarian cancer 
cells through the PI3K/Akt pathway. 
In summary, this study showed a novel connection among Ubc9, cell proliferation and epithelial 
ovarian cancer. Additional studies are needed to better define how these interactions are initiated and 
regulated, and to demonstrate whether similar effects play a role in vivo. 
3. Experimental Section  
3.1. Reagents 
Mouse-anti-human Ubc9 (sc-271057), mouse-anti-human GAPDH (sc-365062), goat-anti-mouse 
(sc-2005) and goat-anti-rabbit (sc-2005) secondary antibodies were purchased from Santa Cruz (Santa 
Cruz, CA, USA). Primary polyclonal Rabbit-anti-total (No. 4685) and phosphorylated (No. 4058) Akt 
antibodies were from Cell Signaling Technology Inc. (Beverly, MA, USA). Expression vector   
pEGFP-N1, RIPM-1640 and Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum 
(FBS), Trizol reagent, Lipofectamine 2000, restriction endonucleases BamHI, XhoI and G418 
(geneticin) were from Invitrogen (San Diego, CA, USA). E. coli (competent cells) JM109 were from 
Toyo (Tokyo, Japan). PCR primers and agarose gel were from Sangon Biotech (Shanghai China). 
Reverse Transcription Polymerase Chain Reaction (RT-PCR) kit and reagents, SYBR Ex Script
TM  
RT-PCR Kit were from Takara (Dalian, China). siRNAs targeted Ubc9 and scrambles were from 
Genkan (Shanghai, China). Ethylenediamine tetraacetic acid (EDTA), dimethyl sulfoxide (DMSO) and 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were from Amresco (Solon, OH, 
USA). PI3K inhibitor LY294002 was from Promega (Madison, WI, USA). BCA Protein Assay Kit and 
ECL kit were from Pierce (Rockford, IL, USA). 
3.2. Cell Culture 
Three human ovarian cell lines were used in this study. HO8910 and CAOV3 cells were grown in 
DMEM and A2780 cells were grown in RPMI-1640 medium. Both were supplemented with 10% FBS 
and maintained continuously in a humidified, 5% CO2 incubator at 37 °C. 
3.3. Immunohistochemical Analysis 
Frozen sections of ovarian samples were incubated with mouse primary anti-Ubc9 antibody   
or purified mouse IgG, horseradish peroxidase-conjugated goat anti-mouse IgG and   
3, 3-diaminobenzidine successively. Sections were then counterstained with hematoxylin. 
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3.4. Quantitative Real-Time PCR 
Total RNA from cells were extracted using Trizol (Invitrogen, Carlsbad, CA, USA) according to 
the manufacturer’s instructions and 2 μg of each total RNA sample was aliquoted to synthesize cDNA 
using the Reverse Transcription System (TaKaRa, Tokyo, Japan). The real-time PCR was run using in 
a 25 µL reaction volume on 96-well plates by using the SYBR Ex Script
TM RT-PCR Kit (TaKaRa, 
Tokyo, Japan) according to the manufacturer’s instructions on the ABI Prism 7,500 Detection System 
(Applied Biosystems, Foster City, CA, USA). The primers for human Ubc9 were F: 5'-GTC CTC CAC 
CTG TCC GCT AC-3', R: 5'-TCT TGC CAA ACC AAT CCC T-3' (PCR product size, 476 bp); the 
primers for human GAPDH were F: 5'-GAA GGT GAA GGT CGG AGT C-3', R: 5'-GAA GAT GGT 
GAT GGG ATT TC-3' (PCR product size, 230 bp). All reactions were done in duplicate and all 
experiments were repeated at least three times. Levels of mRNA were quantified based on the ratio of 
Ubc9 mRNA/GAPDH mRNA using the 2-ΔΔCT method as described by the manufacturer   
(User Bulletin #2, Applied Biosystems, Foster City, CA, USA).  
3.5. Western Blot  
Following treatment, the cells were packed by centrifuging the cells for 3 min at 200 × g, and 
homogenized in ice-cold fractionation buffer (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 150 mM NaCl, 
1% Triton X-100, 1 mM PMSF, 10 μg/mL leupeptin, 10 μg /mL pepstatin A, 10 μg /mL aprotinin,  
1 mM sodium orthovanadate (Na3VO4), 10 mM sodium pyrophosphate (Na4P2O7) and 50 mM sodium 
fluoride (NaF)). The cell lysate was incubated on ice for 15 min and then centrifuged at 20,000 × g for 
30 min at 4 °C. The cytosolic fraction was collected and subjected to SDS-PAGE with a 10% running 
gel. Protein concentrations were determined by the BCA(Bicinchoninic Acid) Protein Assay Kit. The 
proteins were transferred to a polyvinylidene fluoride membrane. The membrane was incubated 
successively with 5% bovine serum albumin in tris tween buffered saline (TTBS) at room temperature 
for 1 h, with different first antibodies at 4 °C for 12 h, and then with horseradish peroxidase-labeled 
second antibody for 1 h. After each incubation, the membrane was washed extensively with TTBS, and 
the immunoreactive band was detected with ECL-detecting reagents. 
3.6. Construction of Plasmid and Generation of Stably Transfected Cell Lines 
The Ubc9 gene was amplified by PCR with human leukocyte genomic DNA as a template and 
primers according to the Ubc9 gene sequence (Gene Bank Accession Number: M003345), sense 
primer, 5'-GTC CTC CAC CTG TCC GC TA C-3', and antisense primer, 5'-TCT TGC CAA ACC 
AAT CCC T-3', under the following conditions: denaturation at 94 °C for 9 min, followed by 30 cycles 
of 94 °C for 1 min, 58 °C for 30 s and 72 °C for 40 s, then extension at 72 °C for 10 min. The PCR 
products were ligated into the pUCM-T vector to clone Ubc9 gene, and the DNA sequence was 
determined by BigDye terminator cycle sequencing ready reaction kit and a DNA sequencer (ABI 
Genetic Analyzer; Perkin-Elmer/Applied Biosystems, Foster City, CA, USA). Then the Ubc9 gene in  
pUCM-T was cut out by double digestion with restriction enzymes, XhoI and BamHI, and ligated into 
the XhoI and BamHI sites of the pEGFP-N1 vector to yield pEGFP-N1-Ubc9. HO8910 transfected 
with plasmid containing pEGFP-N1-Ubc9, empty vector only, or medium were served as Int. J. Mol. Sci. 2013, 14  11069 
 
 
experimental, vehicle control, and blank control groups, respectively. Cells were transfected by vectors 
with Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s protocol. 
In brief, normal growth media were replaced by serum-free medium when cells were seeded at 70% 
confluence in a 6-well plate. Transfection was performed using 2 µg (1 µg/µL) DNA and 5 µL of 
Lipofectamine™ 2000 Reagent (Invitrogen, Carlsbad, CA, USA).The serum-free media were replaced 
by normal growth media after 16 h of transfection. After 48 h of transfection, HO8910 cells expressing 
EGFP-Ubc9 were selected in the presence of G418 (0.4 mg/mL). Then, several stable transfected cells 
were cloned. Each clone was identified by fluorescence microscopy and Western blot analysis for 
expression of Ubc9 (or Ubc9 fusions).  
3.7. siRNA Treatment 
Three siRNA Oligos targeting Ubc9 (Ubc9-siRNA) and negtive control (scrambled siRNA) were 
purchased from Genkan (Shanghai, China). The scrambled siRNA were used as no significant controls 
(NOS). The two complementary oligonucleotides for the three siRNA are as following: siRNA1-Ubc9, 
sense 5'-CAA CGA GGU AUG UUA CUG ATT-3' and antisense 5'-GUU GCU CCA UAC AAU 
GAC UTT-3'; siRNA2-Ubc9, sense 5'-CGU CGC UGG AAC UCC GUA GTT-3' and antisense   
5'-GCA GCG ACC UUG AGG CAU CTT-3'; siRNA3-Ubc9, sense 5'- AGA UUU CAA CGA GGU 
AUG UTT-3' and antisense 5'-GCA GCG ACC UUG AGU CAU CTT-3'. The plasmids were 
transfected into HO8910-Ubc9 cells using Lipofectamine
TM 2000 transfection reagent (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturers’ instructions. 
3.8. Cell Proliferation Assay 
HO8910-Ubc9 and HO8910-pEGFP-N1 cells (4 × 10
3 cells per well) were plated into 96-well 
plates, HO8910 cells without any treatment were used as controls. HO8910-Ubc9 (4 × 10
3 cells per 
well) were plated into 96-well plates in triplicate prior to Ubc9-siRNAs or scrambled siRNA for 48 h 
respectively and then incubated. Cell proliferation was assessed at time point of 0, 24, 48, 72 h using 
MTT assay according to the manufacturer’s instructions. In brief, MTT was added to the culture 
medium to yield a final MTT concentration of 0.5 mg/mL and the incubation was continued for 4 h at 
37 °C. The cell lysates were dissolved with DMSO (150 μL/well) at room temperature for 10 min. 
Results were obtained by measuring the absorbance at a wavelength of 490 nm. The test was repeated 
three times. 
3.9. Statistical Analysis 
Quantitative data are presented as the means ± SEM determined from the indicated number of 
experiments. Statistical analysis was based on Student’s t-test for comparison of two groups or   
one-way ANOVA for multiple comparisons. p < 0.05 was used to determine statistical significance. 
4. Conclusions  
In summary, the present study demonstrated that Ubc9 gene plays an important role in cell 
proliferation of EOC at least partially through PI3K/Akt signaling pathway. Int. J. Mol. Sci. 2013, 14  11070 
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